Register Now for The Outlook on Active Nutrition

Regulatory

Cardiovascular-health ingredients are probably the main beneficiaries of EFSA rulings. What is the significance of this, and what are the opportunities for the industry?

In a letter to FDA, Jarrow L. Rogovin asks that Daniel Fabricant, PhD, be removed from his post as director of FDA’s Division of Dietary Supplement Programs and for FDA to extend the NDI guidance comment period by a year.

The GRAS acceptance follows on heels of recent FDA acknowledgement of a new dietary ingredient (NDI) notification for Superba krill oil.